Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Other Operating Expenses: 2014-2024

Historic Other Operating Expenses for Fortress Biotech (FBIO) over the last 11 years, with Dec 2024 value amounting to $23.7 million.

  • Fortress Biotech's Other Operating Expenses rose 29.03% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 million, marking a year-over-year decrease of 33.35%. This contributed to the annual value of $23.7 million for FY2024, which is 30.57% down from last year.
  • According to the latest figures from FY2024, Fortress Biotech's Other Operating Expenses is $23.7 million, which was down 30.57% from $34.1 million recorded in FY2023.
  • In the past 5 years, Fortress Biotech's Other Operating Expenses registered a high of $41.6 million during FY2021, and its lowest value of $14.6 million during FY2020.
  • Moreover, its 3-year median value for Other Operating Expenses was $30.8 million (2022), whereas its average is $29.5 million.
  • Per our database at Business Quant, Fortress Biotech's Other Operating Expenses surged by 185.21% in 2021 and then tumbled by 30.57% in 2024.
  • Yearly analysis of 5 years shows Fortress Biotech's Other Operating Expenses stood at $14.6 million in 2020, then skyrocketed by 185.21% to $41.6 million in 2021, then dropped by 26.06% to $30.8 million in 2022, then climbed by 10.89% to $34.1 million in 2023, then crashed by 30.57% to $23.7 million in 2024.